CClinicalTrials.gg
Sign In
TerminatedNCT03775226Updated Oct 3, 2023

ChampioNIR® SFA Stent EFS Study

An interventional study of ChampioNIR® SFA Stent in Peripheral Arterial Disease, sponsored by Medinol Ltd.. Terminated at 3 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by Medinol Ltd. · Not applicable, Interventional, and Treatment

Why this study was terminated
The study objective was achieved. Patients are no longer being examined or receiving intervention.
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

An Early Feasibility Study to Assess Safety and Efficacy of the ChampioNIR® SFA Stent in the Treatment of Patients with Femoro-Popliteal Disease

Read the detailed description

Device Overview:

The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.

Objectives:

  • To assess the safety and feasibility of delivery and implantation of ChampioNIR® SFA Stent.
  • To assess the early and long term ability of the stent to maintain vessel patency.
  • To assess the long term safety of the ChampioNIR® SFA Stent.

This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation. All enrolled patients will be followed up at 30 days and up to 36 months. The follow-up visits will include patency evaluation by duplex ultrasound.

Primary efficacy endpoint: Primary patency of the target lesion at 6 months. Primary patency is defined as the absence of target lesion restenosis (defined by Duplex ultrasound (US) peak systolic velocity ratio (PSVR) >2.4) Primary safety endpoint: Composite rate of freedom from all-cause death, target vessel revascularization or any amputation of the index limb through 30 days following stent implantation.

Secondary efficacy endpoints:

  1. Primary patency defined by Duplex US peak systolic velocity ratio (absence of restenosis which defined by Duplex US PSVR >2.4) at 30 days and 12 months.
  2. Acute device success, defined as achievement of a final residual diameter stenosis of \<50% by Quantitative Angiography (QA), using the assigned treatment only.
  3. Acute procedural success, defined as device success with \<50% residual stenosis immediately after stent placement or mean trans-stenotic pressure gradient \<5 mmHg, and without the occurrence of death, amputation or repeat revascularization of the target lesion during the hospital stay.
  4. Acute technical success, defined as the attainment of \<50% residual stenosis by QA by any percutaneous method as determined by the angiographic core laboratory.

  5. The following endpoints at 30 days 6, 12, 24 and 36 months:

    • Secondary Patency (absence of restenosis which is defined as Duplex US PSVR ≥ 2.4)
    • Change of Rutherford classification from baseline
    • Change of resting ankle-brachial index (ABI) from baseline
    • Change in walking impairment questionnaire from baseline
    • Change in six minute walk test from baseline

Secondary safety endpoints:

  1. Combined rate of death at 30 days, target lesion revascularization (TVR), index limb amputation and increase in Rutherford-Becker Classification by ≥2 classes (as compared to post-procedural assessment) throughout 12 months.

  2. Stent fracture at 30 days 6, 12, 24 and 36 months. Stent fractures will be analyzed by a two-view X-ray evaluation by a designated core laboratory, compared with a baseline two-view X-ray taken before discharge and defined as type I, II, III, IV or V as follows:

    • Type I - a single strut fracture only.
    • Type II - multiple single nitinol stent fractures that can occur at different sites.
    • Type III - multiple nitinol stent fractures resulting in complete transverse linear fracture but without stent displacement.
    • Type IV - a complete transverse linear type III fracture with stent displacement.
    • Type V - a spiral dissection of a stent.
  3. Freedom at 30 days from all-cause death, index limb amputation above the ankle and TVR.

  4. The following endpoints will be assessed at 30 days, 6, 12, 24 and 36 months:

    1. All-cause death
    2. Amputation (above the ankle)-Free Survival (AFS)
    3. Target Vessel Revascularization (TVR)
    4. Re-intervention for treatment of thrombosis of the target vessel or embolization to its distal vasculature

  5. Major Adverse Limb Events (MALE) at 30 days, 6, 12, 24 and 36 months:

    1. Stent thrombosis
    2. Clinically apparent distal embolization (defined as causing end-organ damage, e.g. lower extremity ulceration, tissue necrosis, or gangrene)
    3. Procedure-related arterial rupture
    4. Acute limb ischemia
    5. Target limb amputation
    6. Procedure related bleeding event requiring transfusion

Sample Size and Statistical Analysis:

The study is an early feasibility study and is not powered towards finding significant differences in the primary endpoints. The sample size of up to 30 patients will allow for the evaluation of feasibility and safety of the procedure, to support the initiation of a pivotal study. No formal statistical power calculations were conducted.

02

Conditions studied

  • Peripheral Arterial Disease
03

In context

Peripheral Arterial Disease

1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.

This study's enrollment of 22 is below the median of 74 across 1,066 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Medinol Ltd. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥ 18 years and of age of legal consent.
  2. Subject has lifestyle limiting claudication or rest pain (Rutherford-Becker scale 2-4) with a resting ankle-brachial index/toe-brachial index (ABI/TBI) \<0.90/0.80.
  3. A single superficial femoral artery lesion with >50% stenosis or total occlusion.
  4. Stenotic lesion(s) or occluded length within the same vessel (one long or multiple serial lesions) ≥ 40 mm to ≤ 140 mm.
  5. Reference vessel diameter (RVD) ≥ 3.0 mm and ≤ 6.0 mm by visual assessment.
  6. Target lesion located with the distal point at least 3 cm above the knee joint, defined as the distal end of the femur at the knee joint, and proximal point at least 2 cm below the origin of the profunda femoris (deep femoral artery).
  7. Patent infra-popliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (\<50% stenosis) to the ankle or foot.
  8. The target lesion(s) can be successfully crossed with a guide wire and dilated.
  9. The subject is eligible for standard surgical repair, if necessary.
  10. Subjects are willing to comply with scheduled visits and tests and are able and willing to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Thrombophlebitis or deep venous thrombus, within the previous 30 days.
  2. Presence of thrombus in the treated vessel as visualized by angiography, prior to crossing the lesion.
  3. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.
  4. Poor aortoiliac or common femoral "inflow" (i.e. angiographically defined >50% stenosis of the iliac or common femoral artery) that would be deemed inadequate to support a femoro-popliteal bypass graft and was not successfully treated prior to treatment of the target lesion.
  5. Presence of residual ≥30% stenosis after either PTA or stenting of the inflow lesion.
  6. Presence of an ipsilateral arterial artificial graft.
  7. Ipsilateral femoral aneurysm or aneurysm in the SFA or popliteal artery.
  8. Lesions in contralateral SFA/PPA that require intervention during the index procedure, or within 30 days before or after the index procedure;
  9. Required stent placement (in the target or any other lesion) via a retrograde approach.
  10. Required stent placement (in the target or any other lesion) across or within 0.5 cm of the SFA / PFA bifurcation.
  11. Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as in-stent restenosis.
  12. Significant vessel tortuosity or other parameters prohibiting access to the lesion or 90° tortuosity which would prevent delivery of the stent device.
  13. Required stent placement within 1 cm of a previously (in a former procedure) deployed stent.
  14. Use of atherectomy or other atheroablative (e.g. cryoplasty) devices at the time of index procedure.
  15. Restenotic lesion that had previously been treated by atherectomy, laser or cryoplasty within 3 months of the index procedure.
  16. Subject has tissue loss, defined as Rutherford-Becker classification category 5 or 6.
  17. Coronary intervention within 7 days prior to or planned within 30 days after the treatment of the target lesion.
  18. Stroke within the previous 90 days.
  19. Known allergies to any of the following: aspirin, P2Y12 inhibitors (clopidogrel bisulfate, prasugrel, OR ticagrelor), heparin OR bivalirudin, nitinol (nickel titanium), or contrast agent, that cannot be medically managed.
  20. Receiving dialysis or immunosuppressant therapy within the previous 30 days.
  21. Known or suspected active infection at the time of the procedure.
  22. History of neutropenia, coagulopathy, or thrombocytopenia.
  23. Known bleeding or hypercoagulability disorder or significant anemia (Hb\<8.0) that cannot be corrected.
  24. Platelet count \<80,000/μL
  25. International normalized ratio (INR) > 1.5
  26. GFR \<30 ml/min by Cockroft-Gault.
  27. Subject requires general anesthesia for the procedure.
  28. Subject has a co-morbid illness that may result in a life expectancy of less than 1 year
  29. Planned use of a drug coated balloon (DCB) during the index procedure.
  30. Pregnant women or women of child bearing potential who do not have a negative serum or urine pregnancy test documented within 7 days prior to enrollment;
  31. Subject is participating in any investigational study that has not yet reached its primary endpoint.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Single are

    This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.

    Device: ChampioNIR® SFA Stent

Interventions

  • DeviceChampioNIR® SFA Stent

    The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.

    Also known as: ChampioNIR®

06

What researchers measure

Primary outcomes

  1. Primary patency of the target lesion at 6 months.

    Primary patency is defined as the absence of target lesion restenosis (defined by Duplex ultrasound (US) peak systolic velocity ratio (PSVR) \>2.4)

    Time frame: 6 months

  2. Composite rate of freedom

    from all-cause death, target vessel revascularization or any amputation of the index limb through 30 days following stent implantation.

    Time frame: 30 Day

Secondary outcomes

  1. Primary patency defined by Duplex US

    Primary patency defined by Duplex US peak systolic velocity ratio (absence of restenosis which defined by Duplex US PSVR \>2.4

    Time frame: 30 days and 12 months.

  2. Acute device success

    defined as achievement of a final residual diameter stenosis of \<50% by Quantitative Angiography (QA), using the assigned treatment only.

    Time frame: index procedure

  3. Acute procedural success

    defined as device success with \<50% residual stenosis immediately after stent placement or mean trans-stenotic pressure gradient \<5 mmHg, and without the occurrence of death, amputation or repeat revascularization of the target lesion during the hospital stay.

    Time frame: index procedure

  4. Acute technical success

    defined as the attainment of \<50% residual stenosis by QA by any percutaneous method as determined by the angiographic core laboratory.

    Time frame: index procedure

  5. Secondary Patency absence of restenosis which is defined as Duplex US

    Secondary Patency (absence of restenosis which is defined as Duplex US PSVR ≥ 2.4)

    Time frame: 30 days 6, 12, 24 and 36 months

  6. Combined rate 30 day

    of death at 30 days, target lesion revascularization (TVR), index limb amputation and increase in Rutherford-Becker Classification by ≥2 classes (as compared to post-procedural assessment)

    Time frame: 12 months

  7. Stent fractures will be analyzed by a two-view X-ray evaluation by a designated core laboratory, compared with a baseline two-view X-ray taken before discharge and defined as type I, II, III, IV or V as follow

    * Type I - a single strut fracture only. * Type II - multiple single nitinol stent fractures that can occur at different sites. * Type III - multiple nitinol stent fractures resulting in complete transverse linear fracture but without stent displacement. * Type IV - a complete transverse linear type III fracture with stent displacement. * Type V - a spiral dissection of a stent.

    Time frame: 30 days 6, 12, 24 and 36 months

  8. Freedom from all-cause death, index limb amputation above the ankle and TVR.

    Clinical: The number of patients who die from all causes

    Time frame: 30 days

  9. All-cause death

    Clinical: The number of patients who die from all causes

    Time frame: 30 days, 6, 12, 24 and 36 months

  10. The following Major Adverse Limb Events will be evaluated either by angiography or clinical examination. These will be assessed by reviewing angiograms by the core-lab and clinical events will be adjudicated by a CEC

    1. Stent thrombosis 2. Clinically apparent distal embolization (defined as causing end-organ damage, e.g. lower extremity ulceration, tissue necrosis, or gangrene) 3. Procedure-related arterial rupture 4. Acute limb ischemia 5. Target limb amputation 6. Procedure related bleeding event requiring transfusion These are clinical events, the unit of measure for all is - number of patients with any event

    Time frame: 30 days, 6, 12, 24 and 36 months

  11. Rutherford classification

    Change of Rutherford classification from baseline It is defined as follows, with increasing severity: 1. - Mild Claudication - short duration 2. - Moderate Claudication - moderate exercise 3. - Severe Claudication - minor exertion 4. - Rest Pain 5. - Minor Tissue Loss 6. - Major Tissue Loss

    Time frame: 30 days 6, 12, 24 and 36 months

  12. resting ankle-brachial index

    Change of resting ankle-brachial index (ABI) from baseline Ankle Brachial Index (ABI) is a standard measure defined as: The systolic blood pressure at the ankle divided by the systolic blood pressure at the upper arm (brachial artery) A ratio below 0.9 is considered significant

    Time frame: 30 days 6, 12, 24 and 36 months

  13. walking impairment questionnaire

    Change in walking impairment questionnaire from baseline The questionnaire will be used to assess walking capability in patients with Peripheral Arterial Disease (to evaluate the walking impairment and the efficacy of an intervention to improve walking ability in patients with Peripheral Arterial Disease, PAD).\\ The patients will be required to address their walking difficulties and grade them on an increased severity scale.

    Time frame: 30 days 6, 12, 24 and 36 months

  14. six minute walk test

    Change in six minute walk test from baseline

    Time frame: 30 days 6, 12, 24 and 36 months

  15. Amputation (above the ankle)

    Amputation (above the ankle)-Free Survival (AFS)

    Time frame: 30 days, 6, 12, 24 and 36 months

  16. Target Vessel Revascularization

    Target Vessel Revascularization (TVR) Will be measured by the number of patients with the event

    Time frame: 30 days, 6, 12, 24 and 36 months

  17. Re-intervention for treatment of thrombosis of the target vessel or embolization to its distal vasculature

    Re-intervention for treatment of thrombosis of the target vessel or embolization to its distal vasculature Will be measured by the number of patients with the event

    Time frame: 30 days, 6, 12, 24 and 36 months

07

Study locations

3 sites
  • Hadassah Medical Center
    Jerusalem, Israel
  • Rabin Medical Center
    Petah tikva, Israel
  • Sourasky Medical Center
    Tel Aviv, Israel
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03775226
Lead sponsor
Medinol Ltd.
Responsible party
Sponsor
First posted
Dec 13, 2018
Start date
Oct 27, 2019
Primary completion
Aug 26, 2021
Completion
Jan 30, 2023
Last update
Oct 3, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Peripheral Arterial Disease→

Other studies from this sponsor

Medinol Ltd.

Start the discussion